Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;88(4):411-413.
doi: 10.1016/j.eururo.2025.05.035. Epub 2025 Jun 12.

Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes

Sam S Chang  1 , Bryn Launer  2 , Vikram Narayan  3 , Dattatraya Patil  3 , Michael A O'Donnell  4 , Patrick J Hensley  5 , John A Taylor  6 , Roger Li  7 , Mario I Fernandez  8 , Haochen Zhang  9 , Viswesh Krishna  9 , Damir Vrabac  9 , Waleed M Abuzeid  9 , Vivek Nimgaonkar  9 , Drew Watson  9 , Trevor J Royce  9 , Lesli A Kiedrowski  9 , Anirudh Joshi  9 , Badrinath R Konety  10 , Philippe E Spiess  7 , Stephen B Williams  11 , Vignesh T Packiam  12 , Ashish M Kamat  13 , Yair Lotan  14 , Siamak Daneshmand  15
Affiliations

Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes

Sam S Chang et al. Eur Urol. 2025 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Haochen Zhang, Viswesh Krishna, Damir Vrabac, Waleed M. Abuzeid, Vivek Nimgaonkar, Trevor J. Royce, Lesli A. Kiedrowski, and Anirudh Joshi are employees of Valar Labs and hold stock options in the company. Drew Watson is a consultant for Valar Labs. Badrinath R. Konety, Stephen B. Williams, Vignesh T. Packiam, Ashish M. Kamat, and Yair Lotan have received advisory fees from Valar Labs. The remaining authors have nothing to disclose.

Figures

Fig. 1 –
Fig. 1 –
HG RFS and MIBC PFS stratified by AUA and EAU risk groups and CHAI biomarker status. (A) EAU risk group was not significantly associated with HG RFS (HR 1.47, 95% CI 0.96–2.23; p = 0.074). (B) AUA risk group was significantly associated with HG RFS (HR 1.93, 95% CI 1.07–3.48; p = 0.029). (C) CHAI biomarker presence was significantly associated with HG RFS (HR 2.23, 95% CI 1.45–3.44; p < 0.001). (D) EAU risk group was not significantly associated with MIBC PFS (HR 1.32, 95% CI 0.40–4.32; p = 0.7). (E) AUA risk group was not significantly associated with MIBC PFS (HR 1.39, 95% CI 0.30–6.44; p = 0.7). (F) The artificial intelligence component of the CHAI biomarker * was significantly associated with MIBC PFS (HR 4.55, 95% CI 1.39–14.92; p = 0.012). HG = high-grade; RFS = recurrence-free survival; MIBC = muscle-invasive bladder cancer; PFS = progression-free survival; AUA = American Urological Association; EAU = European Association of Urology; CHAI = Computational Histology Artificial Intelligence; IR = intermediate risk; HiR = high risk; HR = hazard ratio; CI = confidence interval. *CHAI biomarker without addition of any clinical variable.
See this image and copyright information in PMC

References

    1. Babjuk M, Burger M, Capoun O, et al. European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2022;81:75–94. - PubMed
    1. Holzbeierlein JM, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol 2024;211:533–8. - PubMed
    1. Tan WS, Steinberg G, Witjes JA, et al. Intermediate-risk non–muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505–16. - PubMed
    1. Ajami T, Han S, Blachman-Braun R, et al. Optimal management for primary high grade Ta bladder cancer: role of re-staging TURBT and intravesical adjuvant therapy. BJUI Compass 2024;5:913–9. 10.1002/bco2.363. - DOI - PMC - PubMed
    1. Lotan Y, Krishna V, Abuzeid WM, et al. Predicting response to intravesical bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer using an artificial intelligence–powered pathology assay: development and validation in an international 12-center cohort. J Urol 2025;213:192–204. - PMC - PubMed

LinkOut - more resources